These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22594381)

  • 1. Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant Gram-negative pathogens.
    Czihal P; Knappe D; Fritsche S; Zahn M; Berthold N; Piantavigna S; Müller U; Van Dorpe S; Herth N; Binas A; Köhler G; De Spiegeleer B; Martin LL; Nolte O; Sträter N; Alber G; Hoffmann R
    ACS Chem Biol; 2012 Jul; 7(7):1281-91. PubMed ID: 22594381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel apidaecin 1b analogs with superior serum stabilities for treatment of infections by gram-negative pathogens.
    Berthold N; Czihal P; Fritsche S; Sauer U; Schiffer G; Knappe D; Alber G; Hoffmann R
    Antimicrob Agents Chemother; 2013 Jan; 57(1):402-9. PubMed ID: 23114765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular uptake of apidaecin 1b and related analogs in Gram-negative bacteria reveals novel antibacterial mechanism for proline-rich antimicrobial peptides.
    Berthold N; Hoffmann R
    Protein Pept Lett; 2014 Apr; 21(4):391-8. PubMed ID: 24164266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models.
    Szabo D; Ostorhazi E; Binas A; Rozgonyi F; Kocsis B; Cassone M; Wade JD; Nolte O; Otvos L
    Int J Antimicrob Agents; 2010 Apr; 35(4):357-61. PubMed ID: 20031377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
    Hamouche E; Sarkis DK
    Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens.
    Knappe D; Piantavigna S; Hansen A; Mechler A; Binas A; Nolte O; Martin LL; Hoffmann R
    J Med Chem; 2010 Jul; 53(14):5240-7. PubMed ID: 20565063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationic amphiphilic alpha-helical peptides for the treatment of carbapenem-resistant Acinetobacter baumannii infection.
    Huang Y; Wiradharma N; Xu K; Ji Z; Bi S; Li L; Yang YY; Fan W
    Biomaterials; 2012 Dec; 33(34):8841-7. PubMed ID: 22925814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant gram-negative bacterial infections after liver transplantation - spectrum and risk factors.
    Zhong L; Men TY; Li H; Peng ZH; Gu Y; Ding X; Xing TH; Fan JW
    J Infect; 2012 Mar; 64(3):299-310. PubMed ID: 22198738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved.
    Ostorhazi E; Holub MC; Rozgonyi F; Harmos F; Cassone M; Wade JD; Otvos L
    Int J Antimicrob Agents; 2011 May; 37(5):480-4. PubMed ID: 21353493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-resistant gram-negative infections. Bringing back the old.
    Chan-Tompkins NH
    Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Schmidt R; Knappe D; Wende E; Ostorházi E; Hoffmann R
    Front Chem; 2017; 5():15. PubMed ID: 28373972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activity of optimized apidaecin and oncocin peptides against a multiresistant, KPC-producing Klebsiella pneumoniae strain.
    Ostorhazi E; Nemes-Nikodem É; Knappe D; Hoffmann R
    Protein Pept Lett; 2014 Apr; 21(4):368-73. PubMed ID: 24164263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
    Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial potential of hGlyrichin encoded by a human gene.
    Sha J; Zhao G; Chen X; Guan W; He Y; Wang Z
    J Pept Sci; 2012 Feb; 18(2):97-104. PubMed ID: 22083756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing bacteriology of abdominal and surgical sepsis.
    Chen YH; Hsueh PR
    Curr Opin Infect Dis; 2012 Oct; 25(5):590-5. PubMed ID: 22744317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.